A polypeptide drug carrier for maternal delivery and prevention of fetal exposure

Journal of Drug Targeting

Volumn 22, Issue 10, 2014, Pages 935-947

  George, Eric M ^a   Liu, Huiling ^a   Robinson, Grant G ^a   Bidwell, Gene L ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Drug delivery; Elastin like polypeptide; Fetal exclusion; Placental transport; Preeclampsia; Pregnancy

Indexed keywords

ELASTIN; POLYPEPTIDE; DRUG CARRIER; PEPTIDE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHORION VILLUS; DISTRIBUTION HALF-LIFE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SAFETY; ELIMINATION RATE CONSTANT; EX VIVO STUDY; FEMALE; FLUORESCENCE; FLUORESCENCE IMAGING; HISTOLOGY; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; NONHUMAN; PLASMA CLEARANCE; PLASMA HALF LIFE; PREGNANCY; PRENATAL DRUG EXPOSURE; PROTEIN PURIFICATION; PROTEIN STABILITY; RAT; ANIMAL; CHEMISTRY; FETOMATERNAL TRANSFUSION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PLACENTA; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ELASTIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MATERNAL-FETAL EXCHANGE; PEPTIDES; PLACENTA; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 84907924532     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2014.950666     Document Type: Article

References (56)

1. Alexander BT, Rinewalt AN, Cockrell KL, et al. Endothelin type a receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure. Hypertension 2001;37:485-9.
2. Taniguchi T, Muramatsu I. Pharmacological knockout of endothelin ET(A) receptors. Life Sci 2003;74:405-9.
3. Fenakel K, Fenakel G, Appelman Z, et al. Nifedipine in the treatment of severe preeclampsia. Obstet Gynecol 1991;77:331-7.
4. Sibai BM, Barton JR, Akl S, et al. A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term. Am J Obstet Gynecol 1992;167:879-84.
5. Bartels PA, Hanff LM, Mathot RA, et al. Nicardipine in preeclamptic patients: placental transfer and disposition in breast milk. BJOG 2007;114:230-3.
6. Firan M, Bawdon R, Radu C, et al. The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans. Int Immunol 2001;13:993-1002.
7. Leach JL, Sedmak DD, Osborne JM, et al. Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport. J Immunol Baltim Md 1996;157:3317-22.
8. Story CM, Mikulska JE, Simister NE. A major histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus. J Exp Med 1994;180:2377-81.
9. Galbraith GM, Galbraith RM, Faulk WP. Immunological studies of transferrin and transferrin receptors of human placental trophoblast. Placenta 1980;1:33-46.
10. McArdle HJ, Morgan EH. Transferrin and iron movements in the rat conceptus during gestation. J Reprod Fertil 1982;66:529-36.
11. Yang H, Sun C, Fan Z, et al. Effects of gestational age and surface modification on materno-fetal transfer of nanoparticles in murine pregnancy. Sci Rep 2012;2:847.
12. Myllynen PK, Loughran MJ, Howard CV, et al. Kinetics of gold nanoparticles in the human placenta. Reprod Toxicol Elmsford N 2008;26:130-7.
13. Yamashita K, Yoshioka Y, Higashisaka K, et al. Silica and titanium dioxide nanoparticles cause pregnancy complications in mice. Nat Nanotechnol 2011;6:321-8.
14. Chu M, Wu Q, Yang H, et al. Transfer of quantum dots from pregnant mice to pups across the placental barrier. Small Weinh Bergstr Ger 2010;6:670-8.
15. Zalgevic?ien-e V, Kulvietis V, Bulotien-e D, et al. The effect of nanoparticles in rats during critical periods of pregnancy. Med Kaunas Lith 2012;48:256-64.
16. Menjoge AR, Rinderknecht AL, Navath RS, et al. Transfer of PAMAM dendrimers across human placenta: prospects of its use as drug carrier during pregnancy. J Control Release 2011;150:326-38.
17. Bidwell GL, Raucher D. Cell penetrating elastin-like polypeptides for therapeutic peptide delivery. Adv Drug Deliv Rev 2010;62: 1486-96.
18. Urry DW, Luan C-H, Parker TM, et al. Temperature of polypeptide inverse temperature transition depends on mean residue hydrophobicity. J Am Chem Soc 1991;113:4346-8.
19. Bidwell GL, Raucher D. Therapeutic peptides for cancer therapy. Part I-peptide inhibitors of signal transduction cascades. Expert Opin Drug Deliv 2009;6:1033-47.
20. Raucher D, Moktan S, Massodi I, Bidwell GL. Therapeutic peptides for cancer therapy. Part II-cell cycle inhibitory peptides and apoptosis-inducing peptides. Expert Opin Drug Deliv 2009;6: 1049-64.
21. Bidwell GL, Fokt I, Priebe W, Raucher D. Development of elastinlike polypeptide for thermally targeted delivery of doxorubicin. Biochem Pharmacol 2007;73:620-31.
22. Dreher MR, Raucher D, Balu N, et al. Evaluation of an elastin-like polypeptide-doxorubicin conjugate for cancer therapy. J Control Release 2003;91:31-43.
23. MacKay JA, Chen M, McDaniel JR, et al. Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection. Nat Mater 2009;8:993-9.
24. Moktan S, Perkins E, Kratz F, Raucher D. Thermal targeting of an acid-sensitive doxorubicin conjugate of elastin-like polypeptide enhances the therapeutic efficacy compared with the parent compound in vivo. Mol Cancer Ther 2012;11:1547-56.
25. Moktan S, Ryppa C, Kratz F, Raucher D. A thermally responsive biopolymer conjugated to an acid-sensitive derivative of paclitaxel stabilizes microtubules, arrests cell cycle, and induces apoptosis. Invest New Drugs 2012;30:236-48.
26. Bidwell GL, Perkins E, Hughes J, et al. Thermally targeted delivery of a c-Myc inhibitory polypeptide inhibits tumor progression and extends survival in a rat glioma model. PLoS One 2013;8: e55104.
27. Bidwell GL, Perkins E, Raucher D. A thermally targeted c-Myc inhibitory polypeptide inhibits breast tumor growth. Cancer Lett 2012;319:136-43.
28. Bidwell GL, Raucher D. Application of thermally responsive polypeptides directed against c-Myc transcriptional function for cancer therapy. Mol Cancer Ther 2005;4:1076-85.
29. Bidwell GL, Whittom AA, Thomas E, et al. A thermally targeted peptide inhibitor of symmetrical dimethylation inhibits cancer-cell proliferation. Peptides 2010;31:834-41.
30. Massodi I, Bidwell GL, Raucher D. Evaluation of cell penetrating peptides fused to elastin-like polypeptide for drug delivery. J Control Release 2005;108:396-408.
31. Massodi I, Moktan S, Rawat A,et al. Inhibition of ovarian cancer cell proliferation by a cell cycle inhibitory peptide fused to a thermally responsive polypeptide carrier. Int J Cancer 2010;126: 533-44.
32. Massodi I, Thomas E, Raucher D. Application of thermally responsive elastin-like polypeptide fused to a lactoferrin-derived peptide for treatment of pancreatic cancer. Molecules 2009;14: 1999-2015.
33. Shamji MF, Betre H, Kraus VB, et al. Development and characterization of a fusion protein between thermally responsive elastinlike polypeptide and interleukin-1 receptor antagonist: sustained release of a local antiinflammatory therapeutic. Arthritis Rheum 2007;56:3650-61.
34. Shamji MF, Chen J, Friedman AH, et al. Synthesis and characterization of a thermally-responsive tumor necrosis factor antagonist. J Control Release 2008;129:179-86.
35. Shamji MF, Jing L, Chen J, et al. Treatment of neuroinflammation by soluble tumor necrosis factor receptor Type II fused to a thermally responsive carrier. J Neurosurg Spine 2008;9:221-8.
36. Urry DW, Long MM, Cox BA, et al. The synthetic polypentapeptide of elastin coacervates and forms filamentous aggregates. Biochim Biophys Acta 1974;371:597-602.
37. Meyer DE, Chilkoti A. Purification of recombinant proteins by fusion with thermally responsive polypeptides. Nat Biotechnol 1999;17:1112-15.
38. Liu W, Dreher MR, Furgeson DY, et al. Tumor accumulation, degradation and pharmacokinetics of elastin-like polypeptides in nude mice. J Control Release 2006;116:170-8.
39. Meyer DE, Kong GA, Dewhirst MW, et al. Targeting a genetically engineered elastin-like polypeptide to solid tumors by local hyperthermia. Cancer Res 2001;61:1548-54.
40. Urry DW, Parker TM, Reid MC, Gowda DC. Biocompatibility of the bioelastic materials, poly(GVGVP) and its gamma-irradiation cross-linked matrix-summary of generic biological test results. Bioact Compat Polym 1991;6:263-82.
41. Rousselle C, Smirnova M, Clair P, et al. Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity. J Pharmacol Exp Ther 2001;296: 124-31.
42. Bidwell GL, Davis AN, Raucher D. Targeting a c-Myc inhibitory polypeptide to specific intracellular compartments using cell penetrating peptides. J Control Release 2009;135:2-10.
43. Bidwell GL, Raucher D. Enhancing the antiproliferative effect of topoisomerase II inhibitors using a polypeptide inhibitor of c-Myc. Biochem Pharmacol 2006;71:248-56.
44. Liu W, MacKay JA, Dreher MR, et al. Injectable intratumoral depot of thermally responsive polypeptide-radionuclide conjugates delays tumor progression in a mouse model. J Control Release 2010;144: 2-9.
45. Liu W, McDaniel J, Li X, et al. Brachytherapy using injectable seeds that are self-assembled from genetically encoded polypeptides in situ. Cancer Res 2012;72:5956-65.
46. Massodi I, Bidwell GL, Davis A, et al. Inhibition of ovarian cancer cell metastasis by a fusion polypeptide Tat-ELP. Clin Exp Metastasis 2009;26:251-60.
47. Moktan S, Raucher D. Anticancer activity of proapoptotic peptides is highly improved by thermal targeting using elastin-like polypeptides. Int J Pept Res Ther 2012;18:227-37.
48. Heitz F, Morris MC, Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol 2009;157:195-206.
49. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000;183:S1-22.
50. Podymow T, August P. Update on the use of antihypertensive drugs in pregnancy. Hypertension 2008;51:960-9.
51. Lambot MA, Vermeylen D, Noël JC. Angiotensin-II-receptor inhibitors in pregnancy. Lancet 2001;357:1619-20.
52. Roberts JM, Pearson G, Cutler J, Lindheimer M; NHLBI Working Group on Research on Hypertension During Pregnancy. Summary of the NHLBI working group on research on hypertension during pregnancy. Hypertension 2003;41:437-45.
53. George EM, Granger JP. Endothelin: key mediator of hypertension in preeclampsia. Am J Hypertens 2011;24:964-9.
54. Jeyabalan A, Conrad KP. Renal function during normal pregnancy and preeclampsia. Front Biosci J Virtual Libr 2007;12: 2425-37.
55. Moran P, Baylis PH, Lindheimer MD, Davison JM. Glomerular ultrafiltration in normal and preeclamptic pregnancy. J Am Soc Nephrol JASN 2003;14:648-52.
56. George EM, Granger JP. Mechanisms and potential therapies for preeclampsia. Curr Hypertens Rep 2011;13:269-75.